Tagged articles
AI drug discovery
10 articles · Page 1 of 1
The article analyzes why a pre‑launch AI‑driven pharma company can attract a $20 billion valuation, detailing the efficiency promises of AI, the evolving technology stack, the scarcity of talent, and the real bottlenecks that still limit drug discovery.
AI drug discoveryVenture Capitalbiotech talent scarcity
0 likes · 12 min read

The June 27 industry roundup covers OpenAI’s limited preview of the three‑tier GPT‑5.6 models and the Daybreak security toolset, a critical Codex logging bug, US regulatory constraints on frontier AI, DeepSeek’s 51‑billion‑yuan funding and hiring surge, major semiconductor IPOs, AI‑driven robotics advances, AI drug‑discovery competitions, and rising AI‑related job trends.
AI drug discoveryAI industryAI security
0 likes · 20 min read


SuanNiMay 2, 2026 · Artificial Intelligence
The article presents a joint molecular model that combines property prediction with molecule reconstruction, introduces a "strangeness" metric to detect distribution shift, validates it on 33 datasets, applies it to a 140k virtual screen, and experimentally discovers seven highly novel kinase inhibitors.
AI drug discoverydistribution shiftjoint molecular model
0 likes · 7 min read

Lilly’s recent RMB 2.75 billion investment in AI-driven drug discovery firm Insilico Medicine signals a strategic shift from using AI as a supplementary tool to a core engine, highlighting both the promise of accelerated target identification and the lingering challenges of clinical validation, data quality, and regulatory acceptance.
AI drug discoveryInsilico MedicineLilly investment
0 likes · 5 min read

The March 30, 2026 AI Tech Daily highlights PaddleOCR surpassing Tesseract with 73.3K stars, GigaWorld's GigaBrain models leading global rankings, Eli Lilly's 2.75 billion‑RMB AI drug‑discovery investment, Doubao joining top‑tier LLMs, Stanford's InfoTok video tokenization breakthrough, Claude's rapid vulnerability exploit, a new Claude model beating Opus 4.6, Node.js core members petitioning to ban AI‑assisted coding, Kimi K2.5 reaching $1 billion monthly revenue, a startup's tiny model delivering 15× inference speed, and Claude's 15 KB engine boosting rendering speed 1,200×.
AI drug discoveryClaudeGigaBrain
0 likes · 6 min read

PropMolFlow, a new flow‑matching model introduced by researchers from the University of Florida and NYU, generates property‑guided molecules up to ten times faster than prior SOTA methods while preserving chemical validity and achieving superior performance on benchmarks such as QM9.
AI drug discoveryFlow MatchingPropMolFlow
0 likes · 7 min read

ReaSyn, a new framework from Nvidia’s research team, treats synthesis pathways as chain‑of‑thought reasoning using a novel Chain‑of‑Reaction representation, achieving the highest reconstruction rates and path diversity in molecule synthesis tasks, and outperforming prior methods across multiple benchmark optimizations.
AI drug discoveryReaSynReinforcement Learning
0 likes · 14 min read

The inaugural Shanghai International Computational Biology Innovation Competition concluded with five finalist teams, awarding a GeminiMol team from ShanghaiTech University first prize for discovering highly active molecules validated by wet experiments, while the event showcased AI-driven drug discovery targeting the NMDA receptor, highlighted the city’s new computational biology action plan, and emphasized talent selection through competition.
AI drug discoveryNMDA receptorShanghai competition
0 likes · 7 min read

The article outlines NVIDIA’s CLARA platform, BioNeMo framework, and GPU‑accelerated tools such as CLARA Parabricks and RAPIDS, demonstrating how AI and high‑performance computing dramatically speed up drug‑target identification, molecular generation, protein structure prediction, and high‑throughput DNA/RNA sequencing, with benchmarks showing up to 80‑fold acceleration.
AI drug discoveryBioNeMoCLARA
0 likes · 11 min read

GraphSynergy integrates network science and graph convolutional networks to predict synergistic anti‑cancer drug combinations by modeling protein‑protein interaction networks, computing therapy and toxicity scores, and outperforming baseline methods on DrugCombDB and Oncology‑Screen datasets, while offering interpretable mechanisms for drug repurposing.
AI drug discoveryGraph Neural Networkscancer therapy
0 likes · 19 min read
